James Knight, MBA
Head of Business Development
Jim Knight brings more than 20 years of experience in creating portfolio value at publicly traded companies. He has extensive experience providing corporate and business development consulting for biotech companies in the US and Europe.
Mr. Knight was previously the Vice President of Portfolio Strategy at Questcor, where he worked to deliver the $5.6 billion acquisition of Questcor by Mallinckrodt Pharmaceuticals, and following that, he led corporate development for BioTime (now Lineage Cell Therapeutics), a regenerative medicine company focused on the development of cellular therapies. Prior to Questcor, he spent seven years at Elan Pharmaceuticals leading global strategic marketing, where he worked on the successful development and commercialization of Tysabri, a monoclonal antibody. He began his career as an Associate Scientist in pharmacology at Biogen, before moving to commercial roles as a market analyst and product manager.
Mr. Knight holds a BS in Biology from the University of Massachusetts, Amherst and earned his MBA at Northeastern University.